Get started
Santen Pharmaceutical Co., Ltd.Santen Pharmaceutical Co., Ltd.Santen Pharmaceutical Co., Ltd.

Santen Pharmaceutical Co., Ltd.

No trades
See on Supercharts
OverviewFinancialsNewsIdeasDiscussionsTechnicalsForecastSeasonalsETFs

SNPHF chart


Full chart

SNPHF upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪3.74 B‬ USD
Dividend yield (indicated)
2.32%
Price to earnings Ratio (TTM)
17.62
Basic EPS (TTM)
0.64 USD
Net income (FY)
‪241.62 M‬ USD
Revenue (FY)
‪2.00 B‬ USD
Shares float
‪293.23 M‬
Beta (1Y)
0.43

Employees


Employees (FY)
‪3.85 K‬
Change (1Y)
+105 +2.80%
Revenue / Employee (1Y)
‪519.57 K‬ USD
Net income / Employee (1Y)
‪62.78 K‬ USD

About Santen Pharmaceutical Co., Ltd.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Takeshi Ito
Website
santen.co.jp
Headquarters
Osaka
Founded
1890
ISIN
JP3336000009
FIGI
BBG000DQQM00
Santen Pharmaceutical Co., Ltd engages in the manufacture and sale of pharmaceutical products and medical devices. It operates through the following segments: Pharmaceuticals and Others. The Pharmaceuticals segment includes prescription ophthalmic drugs, anti-rheumatic pharmaceuticals, and over-the-counter products. The Others segment offers medical equipment and devices. The company was founded by Kenkichi Tagushi in 1890 and is headquartered in Osaka, Japan.

Check out other big names from the same industry as SNPHF.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

SNPHF news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of SNPHF is 11.45 USD — it has increased by 4.09% in the past 24 hours. Watch Santen Pharmaceutical Co., Ltd. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Santen Pharmaceutical Co., Ltd. stocks are traded under the ticker SNPHF.
We've gathered analysts' opinions on Santen Pharmaceutical Co., Ltd. future price: according to them, SNPHF price has a max estimate of 17.56 USD and a min estimate of 11.48 USD. Watch SNPHF chart and read a more detailed Santen Pharmaceutical Co., Ltd. stock forecast: see what analysts think of Santen Pharmaceutical Co., Ltd. and suggest that you do with its stocks.
SNPHF reached its all-time high on Mar 6, 2015 with the price of 70.12 USD, and its all-time low was 6.25 USD and was reached on Nov 8, 2022. View more price dynamics on SNPHF chart.
See other stocks reaching their highest and lowest prices.
SNPHF stock is 3.93% volatile and has beta coefficient of 0.43. Track Santen Pharmaceutical Co., Ltd. stock price on the chart and check out the list of the most volatile stocks — is Santen Pharmaceutical Co., Ltd. there?
Today Santen Pharmaceutical Co., Ltd. has the market capitalization of ‪3.68 B‬, it has increased by 1.26% over the last week.
Yes, you can track Santen Pharmaceutical Co., Ltd. financials in yearly and quarterly reports right on TradingView.
Santen Pharmaceutical Co., Ltd. is going to release the next earnings report on Nov 11, 2025. Keep track of upcoming events with our Earnings Calendar.
SNPHF earnings for the last quarter are 0.12 USD per share, whereas the estimation was 0.17 USD resulting in a −27.54% surprise. The estimated earnings for the next quarter are 0.14 USD per share. See more details about Santen Pharmaceutical Co., Ltd. earnings.
Santen Pharmaceutical Co., Ltd. revenue for the last quarter amounts to ‪476.97 M‬ USD, despite the estimated figure of ‪501.94 M‬ USD. In the next quarter, revenue is expected to reach ‪458.58 M‬ USD.
SNPHF net income for the last quarter is ‪40.79 M‬ USD, while the quarter before that showed ‪58.54 M‬ USD of net income which accounts for −30.33% change. Track more Santen Pharmaceutical Co., Ltd. financial stats to get the full picture.
Santen Pharmaceutical Co., Ltd. dividend yield was 2.54% in 2024, and payout ratio reached 34.62%. The year before the numbers were 2.15% and 45.46% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Sep 26, 2025, the company has ‪3.85 K‬ employees. See our rating of the largest employees — is Santen Pharmaceutical Co., Ltd. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Santen Pharmaceutical Co., Ltd. EBITDA is ‪429.97 M‬ USD, and current EBITDA margin is 24.73%. See more stats in Santen Pharmaceutical Co., Ltd. financial statements.
Like other stocks, SNPHF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Santen Pharmaceutical Co., Ltd. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Santen Pharmaceutical Co., Ltd. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Santen Pharmaceutical Co., Ltd. stock shows the buy signal. See more of Santen Pharmaceutical Co., Ltd. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.